|
XTL Biopharmaceuticals Ltd. (XTLB) DCF -Bewertung
IL | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
XTL Biopharmaceuticals Ltd. (XTLB) Bundle
Unser XTLB DCF-Taschenrechner entwickelt für die Genauigkeit und ermöglicht es Ihnen, die Bewertung von XTL Biopharmaceuticals Ltd. unter Verwendung realer Finanzdaten zu bewerten und vollständige Flexibilität zu bieten, um alle wesentlichen Parameter für erweiterte Projektionen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | .0 | -.9 | -1.0 | -.9 | -.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .8 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -.8 | -.9 | -1.0 | -.9 | -.8 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 6.7 | 6.0 | 6.1 | 3.7 | 2.0 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 |
| EBITAT | -.8 | -.9 | -1.0 | -.9 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | .0 | -.9 | -1.0 | -.9 | .0 | .0 | .0 | .0 | .0 | .0 |
| WACC, % | 9.04 | 9.04 | 9.04 | 9.04 | 9.04 | 9.04 | 9.04 | 9.04 | 9.04 | 9.04 |
| PV UFCF | ||||||||||
| SUM PV UFCF | .0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -1 | |||||||||
| Equity Value | 1 | |||||||||
| Diluted Shares Outstanding, MM | 545 | |||||||||
| Equity Value Per Share | 0.00 |
What You Will Get
- Pre-Filled Financial Model: XTL Biopharmaceuticals Ltd.’s (XTLB) actual data allows for accurate DCF valuation.
- Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
- Instant Calculations: Automatic updates provide real-time results as you make adjustments.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
- Customizable and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasting.
Key Features
- Comprehensive Financial Data: Gain access to precise pre-loaded historical data and future forecasts for XTL Biopharmaceuticals Ltd. (XTLB).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic updates to DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: User-friendly charts and summaries to effectively visualize your valuation outcomes.
- Designed for All Skill Levels: An intuitive layout tailored for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered XTL Biopharmaceuticals data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for XTL Biopharmaceuticals' intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose XTL Biopharmaceuticals Ltd. (XTLB)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Proven Expertise: A team of seasoned professionals with extensive experience in biopharmaceutical development.
- Robust Pipeline: A diverse range of products in various stages of development ensures long-term growth potential.
- Commitment to Quality: Adherence to the highest regulatory standards guarantees the safety and efficacy of our products.
- Strong Partnerships: Collaborations with leading research institutions enhance our capabilities and reach.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for assessing XTL Biopharmaceuticals Ltd. (XTLB) investments.
- Pharmaceutical Finance Teams: Evaluate valuation scenarios to inform corporate strategies in the biotech sector.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in XTL Biopharmaceuticals Ltd. (XTLB).
- Students and Educators: Utilize real-world data to learn and teach financial modeling in the biotech industry.
- Biotech Enthusiasts: Gain insights into how companies like XTL Biopharmaceuticals Ltd. (XTLB) are valued in the market.
What the Template Contains
- Pre-Filled DCF Model: XTL Biopharmaceuticals Ltd.’s (XTLB) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital specific to XTLB.
- Financial Ratios: Assess XTLB’s profitability, leverage, and operational efficiency.
- Editable Inputs: Adjust assumptions such as growth rates, margins, and CAPEX to match your scenarios.
- Financial Statements: Annual and quarterly reports for comprehensive analysis of XTLB.
- Interactive Dashboard: Effortlessly visualize key valuation metrics and outcomes for XTLB.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.